Clinical trial
506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic…
NCT00003545 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003545 |
|---|---|
| Title | 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma |
| Official title | A Phase II Study of 506U78 in Patients With Refractory or Relapsed T-Lineage Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphomas (LBL) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | SWOG Cancer Research Network |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Drug |
| Interventions | nelarabine |
| Enrollment | 35 |
| Start date | Aug 1, 1998 |
| Primary completion | Mar 1, 2007 |
| First posted | Feb 16, 2004 |
| Last update posted | Feb 5, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: